Exelby P R
Pediatric Surgical Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
Urol Clin North Am. 1991 Aug;18(3):589-97.
Wilms' tumor is the most common malignant tumor of the kidney in children. Although only 500 cases per year are diagnosed in the US, the tumor has been studied extensively in the National Wilms' Tumor Committee Cooperative Studies. These prospective studies have led to improved survival and at the same time reduced treatment and complications in the more favorable cases. Similar results have been shown by the European cooperative study group SIOP using different treatment protocols. These studies have identified a group of tumors with unfavorable histology that are more resistant to treatment and will require more intensive protocols. Diagnosis of Wilms' tumor by the finding of a large flank mass in an otherwise healthy-appearing child is usually easy. Imaging techniques of CT or IVU will give accurate confirmation of Wilms' tumor in 95% of children. Modern treatment in the US by radical nephrectomy followed by chemotherapy with or without radiotherapy depends on tumor stage and histology. Early-stage tumors with favorable histology can be controlled by shorter courses of two-drug treatment (dactinomycin and vincristine) without radiation. Advanced tumors respond to treatment but require more intensive chemotherapy combined with radiation. The final challenge is the child with a tumor of unfavorable histology, particularly if there is advanced-stage disease. Whereas Wilms' tumor showing favorable histology now has a survival rate exceeding 90%, survival of those with tumors of unfavorable histology remains poor. The European (SIOP) studies have shown similar survival figures using preoperative chemotherapy. This technique produces shrinkage of tumors, making them less hemorrhagic and producing a lower incidence of rupture at subsequent surgery. Preoperative chemotherapy does not change the histologic diagnosis of Wilms' tumor and is a useful alternative approach for the large hemorrhagic or infiltrating tumors.
肾母细胞瘤是儿童最常见的肾脏恶性肿瘤。尽管在美国每年仅诊断出500例,但该肿瘤在国家肾母细胞瘤委员会合作研究中得到了广泛研究。这些前瞻性研究提高了生存率,同时在病情较为有利的病例中减少了治疗和并发症。欧洲合作研究小组SIOP使用不同的治疗方案也显示了类似的结果。这些研究确定了一组组织学表现不佳的肿瘤,它们对治疗更具抗性,需要更强化的治疗方案。通过在外表健康的儿童中发现侧腹大肿块来诊断肾母细胞瘤通常很容易。CT或IVU等成像技术能在95%的儿童中准确确诊肾母细胞瘤。在美国,现代治疗方法是根治性肾切除术,随后根据肿瘤分期和组织学进行化疗,可联合或不联合放疗。组织学表现良好的早期肿瘤可通过较短疗程的双药治疗(放线菌素D和长春新碱)控制,无需放疗。晚期肿瘤对治疗有反应,但需要更强化的化疗联合放疗。最后的挑战是组织学表现不佳的肿瘤患儿,尤其是处于晚期疾病的患儿。虽然组织学表现良好的肾母细胞瘤现在生存率超过90%,但组织学表现不佳的肿瘤患儿生存率仍然很低。欧洲(SIOP)的研究表明,术前化疗的生存率相似。这种技术可使肿瘤缩小,减少出血,降低后续手术时破裂的发生率。术前化疗不会改变肾母细胞瘤的组织学诊断,对于大的出血性或浸润性肿瘤是一种有用的替代方法。